Skip to main content
. Author manuscript; available in PMC: 2012 May 1.
Published in final edited form as: Eur J Immunol. 2011 Apr 12;41(5):1465–1479. doi: 10.1002/eji.201041241

Figure 4. Distinct conformations between two- vs. four-domain DR2/MOG-35-55 complexes revealed by anti-RTL1000 TCRLs.

Figure 4

DR2 APCs (L466.1 DR*1501 L cell transfectants) were pulsed with MOG-35-55 or MBP-85-99 peptides and tested for (A) the indicated Fab staining by FACS, or (B) activation of the H2-1 MOG-35-55 specific T-cell hybridoma. C) Ag-specific activation of H2-1 MOG-35-55 specific T-cell hybridoma was not affected by the anti-RTL1000 Fabs, as demonstrated by detection of IL-2 secreted (3H-Tdy uptake by CTLL cells incubated with cell supernatants) from the H2-1 T-cell hybridoma activated by DR2*1501 APC in the presence of anti-RTL1000 Fab Abs and control Fab (D2) compared to the inhibitory anti-MHC II Ab (TU39, BD). D) Binding of anti-RTL1000 Fabs and anti-MHC II (TU39, BD) to immobilized RTL1000 and full length recombinant DR2/MOG-35-55 complexes as detected by ELISA. Note lack of reactivity of Fabs to MOG peptide-loaded four-domain DR2 complexes. Data in A–D are representative of at least three independent experiments.